Topics

High-grade gliomas | Treatment | Targeted therapy | Ipilimumab

Home > Publications > Topics > High-grade gliomas > Treatment > Targeted therapy > Ipilimumab

Duerinck J, Lescrauwaet L, Dirven I, Del'haye J, Stevens L, Geeraerts X, Vaeyens F, Geens W, Brock S, Vanbinst AM, Everaert H, Caljon B, Bruneau M, Lebrun L, Salmon I, Kockx M, Tuyaerts S, Neyns B.
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.
Neuro Oncol. 2024 Oct 16:noae177. doi: 10.1093/neuonc/noae177. PMID: 39406392. Interventional study. ˍ

Kesari S, Wojcinski A, Pabla S, Seager RJ, Gill JM, Carrillo JA, Wagle N, Park DJ, Nguyen M, Truong J, Takasumi Y, Chaiken L, Chang SC, Barkhoudarian G, Kelly DF, Juarez TM.
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas.
Oncoimmunology. 2024 Nov 21;13(1):2432728. doi: 10.1080/2162402X.2024.2432728. PMID: 39572979. Interventional study. ˍ

Sahebjam S, Raval RR, Forsyth PA, Enderling H, Tran ND, Arrington JA, Macaulay R, Perlow HK, Palmer JD, Ghose J, Rajappa P, Giglio P, Li Z, Etame AB, Mokhtari S, Cruz-Chamorro RJ, Bhandari M, Thapa R, Robinson TJ, Chen DT, Yu HM.
Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomas.
Neurooncol Adv. 2025 Feb 8;7(1):vdaf033. doi: 10.1093/noajnl/vdaf033. PMID: 40134851. Interventional study. ˍ